NK-TICA / Bicycle Therap - LARVOL DELTA

Modulation of the natural killer cell immune response to tumor with a synthetic tumor -immune cell agonist, NK-TICA™ (AACR 2024) - "In conclusion, NK-TICAs drive NK cell-mediated tumor cell killing and cytokine production in vitro and as such have the potential to catalyze the development of durable anti-tumor immunity in tumor types not well served by current therapies. We hypothesize that utilization of Bicycle® NK-TICA™ as a multifunctional immune cell engager will promote the modulation and anti-tumor activity of peripheral and intra-tumoral NK cells to solid tumors."

Immune cell • Oncology • Solid Tumor

Bicycle Therapeutics to Present at the AACR Annual Meeting 2024 (Businesswire) - "Bicycle Therapeutics plc...announced the acceptance of three abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place in San Diego on April 5-10."

Preclinical • Oncology

In vivo evaluation of NK-TICA®, a novel Bicycle® tumor-targeted immune cell agonist (TICA) designed to engage NK cells (AACR 2023) - "We show that NK cell activation in the tumor is dependent on binding of the TICA® to a tumor antigen highlighting the importance of the precision-guided approach.In vivo proof-of-concept data shown here, in combination with extensive in vitro preclinical characterization of NK-TICA® reported elsewhere, validate this novel class of NK cell engagers as a prospective therapeutic modality.These studies were approved by the Institutional Animal Care and Use Committee (IACUC). The care and use of animals was conducted in accordance with regulations of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)."

Immune cell • IO biomarker • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Modulation of natural killer cell immune response to tumor with novel synthetic tumor -immune cell agonist, NK-TICA(r) (AACR 2023) - "In conclusion, NK-TICAs drive NK cell-mediated tumor cell killing and cytokine production in vitro and as such have the potential to catalyze the development of durable anti-tumor immunity in tumor types not well served by current therapies. We hypothesize that utilization of Bicycle NK-TICA® as a multifunctional immune cell engager will promote the modulation of NK cells, as well as the infiltration and anti-tumor activity of NK cells in solid tumors.®"

Immune cell • Oncology • Solid Tumor

Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting (Businesswire) - "Bicycle Therapeutics plc...announced that the company will present four poster presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place in Orlando, FL on April 14-19, 2023."

Preclinical • Trial status • Oncology • Solid Tumor